her2 Archives -

Market Access/ News/ News/ News/ Oncology

AZ gets FDA nod for Enhertu in first HER2-low cancer

Phil Taylor AstraZeneca, breast cancer, Enhertu, fda, her2, Oncology, regulatory approval 0 Comment

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu as the first targeted therapy for HER2-low breast cancer,

AZ gets FDA nod for Enhertu in first HER2-low cancer

https://pharmaphorum.com/news/az-gets-fda-nod-for-enhertu-in-first-her2-low-cancer/

News/ News/ Oncology

FDA verdict on Enhertu in HER2-low breast cancer due before year-end

Phil Taylor AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, fda, her2, Oncology 0 Comment

AstraZeneca and Daiichi Sankyo will hear back from the FDA before the end of 2022 on their license

FDA verdict on Enhertu in HER2-low breast cancer due before year-end

https://pharmaphorum.com/news/fda-verdict-on-enhertu-in-her2-low-breast-cancer-due-before-year-end/

Market Access/ News/ News/ News/ Oncology

AZ, Daiichi challenge Roche with EU okay for earlier use of Enhertu

Phil Taylor AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, EU, her2, Kadcyla, regulatory approval, Roche, Seagen, Tukysa 0 Comment

AstraZeneca and Daiichi Sankyo have claimed approval in the EU for Enhertu as a second-line therapy for HER2-positive

AZ, Daiichi challenge Roche with EU okay for earlier use of Enhertu

https://pharmaphorum.com/news/az-daiichi-challenge-roche-with-eu-okay-for-earlier-use-of-enhertu/

Market Access/ News/ News/ News/ Oncology

Byondis cues up US, EU decisions on breast cancer ADC in 2023

Phil Taylor AstraZeneca, breast cancer, Byondis, Daiichi Sankyo, Enhertu, her2, Kadcyla, Oncology, Roche 0 Comment

Byondis has filed its HER2-targeting antibody-drug conjugate (ADC) trastuzumab duocarmazine in the US and Europe, setting up possible

Byondis cues up US, EU decisions on breast cancer ADC in 2023

https://pharmaphorum.com/news/byondis-cues-up-us-eu-decisions-on-breast-cancer-adc-in-2023/

Oncology/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis

Redefining the approach to cancer care – a mission to improve patient outcomes

mike.hammerton@pharmaphorum.com breast cancer, cancer care, company profile, Exact Sciences, her2 0 Comment

Each year across Europe, 3.7 million people are diagnosed with a form of cancer, resulting in 1.9 million

Redefining the approach to cancer care – a mission to improve patient outcomes

https://pharmaphorum.com/oncology/redefining-the-approach-to-cancer-care-a-mission-to-improve-patient-outcomes/

Market Access/ News/ News/ News/ Oncology

Enhertu gets breakthrough tag in HER2-low breast cancer

Phil Taylor antibody-drug conjugate, AstraZeneca, breakthrough Therapy, breast cancer, Daiichi Sankyo, Enhertu, her2, Oncology 0 Comment

AstraZeneca and Daiichi Sankyo have claimed a fifth breakthrough designation from the FDA for Enhertu, shortly after showing

Enhertu gets breakthrough tag in HER2-low breast cancer

https://pharmaphorum.com/news/enhertu-gets-breakthrough-tag-in-her2-low-breast-cancer/

Market Access/ News/ News/ News/ Oncology

FDA starts speedy review of Enhertu in lung cancer

Phil Taylor AstraZeneca, Daiichi Sankyo, Enhertu, her2, Non-small cell lung cancer 0 Comment

AstraZeneca and Daiichi Sankyo should only have to wait for six months to hear from the FDA if

FDA starts speedy review of Enhertu in lung cancer

https://pharmaphorum.com/news/fda-starts-speedy-review-of-enhertu-in-lung-cancer/

News/ News/ Oncology

Big day for AZ, Daiichi as Enhertu aces HER2-low breast cancer trial

Phil Taylor AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, her2 0 Comment

Already making inroads as a treatment for HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo’s Enhertu has now shown

Big day for AZ, Daiichi as Enhertu aces HER2-low breast cancer trial

https://pharmaphorum.com/news/big-day-for-az-daiichi-as-enhertu-aces-her2-low-breast-cancer-trial/

News/ News/ Oncology

EMA starts review of Enhertu for HER2+ gastric cancer

Phil Taylor AstraZeneca, Daiichi Sankyo, ema, Enhertu, her2, Oncology, stomach cancer 0 Comment

The EMA has started its review of AstraZeneca and Daiichi Sankyo’s Enhertu for a second indication, as a

EMA starts review of Enhertu for HER2+ gastric cancer

https://pharmaphorum.com/news/ema-starts-review-of-enhertu-for-her2-gastric-cancer/

Trending

her2

Login